Viking Therapeutics, Inc.Viking Therapeutics, Inc.Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪3.34 B‬EUR
−1.305EUR
‪−106.22 M‬EUR
0.00EUR
‪109.09 M‬
Beta (1Y)
0.89
Employees (FY)
36
Change (1Y)
+9 +33.33%
Revenue / Employee (1Y)
0.00EUR
Net income / Employee (1Y)
‪−2.95 M‬EUR

About Viking Therapeutics, Inc.


CEO
Brian Lian
Headquarters
San Diego
Founded
2012
ISIN
US92686J1060
FIGI
BBG01TNXKZW2
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Check out other big names from the same industry as 1VKTX.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
XBI
SPDR S&P BIOTECH ETF
Weight
1.45%
Market value
‪100.88 M‬
USD
VB
Vanguard Small-Cap ETF
Weight
0.04%
Market value
‪66.54 M‬
USD
VBK
Vanguard Small-Cap Growth ETF
Weight
0.09%
Market value
‪37.16 M‬
USD
VXF
Vanguard Extended Market ETF
Weight
0.04%
Market value
‪31.68 M‬
USD
SCHA
Schwab U.S. Small-Cap ETF
Weight
0.10%
Market value
‪18.88 M‬
USD
IWR
iShares Russell Midcap ETF
Weight
0.03%
Market value
‪13.50 M‬
USD
VHT
Vanguard Health Care ETF
Weight
0.05%
Market value
‪8.34 M‬
USD
IWD
iShares Russell 1000 Value ETF
Weight
0.01%
Market value
‪7.69 M‬
USD
LABU
Direxion Daily S&P Biotech Bull 3X Shares
Weight
1.38%
Market value
‪5.84 M‬
USD
IWS
iShares Russell Mid-Cap Value ETF
Weight
0.04%
Market value
‪5.22 M‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of 1VKTX is 28.545 EUR — it has decreased by −8.17% in the past 24 hours. Watch Viking Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange Viking Therapeutics, Inc. stocks are traded under the ticker 1VKTX.
1VKTX stock has fallen by −9.85% compared to the previous week, the month change is a 37.55% rise, over the last year Viking Therapeutics, Inc. has showed a 25.92% increase.
We've gathered analysts' opinions on Viking Therapeutics, Inc. future price: according to them, 1VKTX price has a max estimate of 107.24 EUR and a min estimate of 28.31 EUR. Watch 1VKTX chart and read a more detailed Viking Therapeutics, Inc. stock forecast: see what analysts think of Viking Therapeutics, Inc. and suggest that you do with its stocks.
1VKTX reached its all-time high on Aug 19, 2025 with the price of 39.920 EUR, and its all-time low was 18.985 EUR and was reached on Sep 17, 2025. View more price dynamics on 1VKTX chart.
See other stocks reaching their highest and lowest prices.
1VKTX stock is 13.19% volatile and has beta coefficient of 0.89. Track Viking Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Viking Therapeutics, Inc. there?
Today Viking Therapeutics, Inc. has the market capitalization of ‪3.34 B‬, it has increased by 15.96% over the last week.
Yes, you can track Viking Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Viking Therapeutics, Inc. is going to release the next earnings report on Oct 22, 2025. Keep track of upcoming events with our Earnings Calendar.
1VKTX earnings for the last quarter are −0.49 EUR per share, whereas the estimation was −0.38 EUR resulting in a −29.90% surprise. The estimated earnings for the next quarter are −0.60 EUR per share. See more details about Viking Therapeutics, Inc. earnings.
Viking Therapeutics, Inc. revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
1VKTX net income for the last quarter is ‪−55.65 M‬ EUR, while the quarter before that showed ‪−42.18 M‬ EUR of net income which accounts for −31.96% change. Track more Viking Therapeutics, Inc. financial stats to get the full picture.
No, 1VKTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 18, 2025, the company has 36 employees. See our rating of the largest employees — is Viking Therapeutics, Inc. on this list?
Like other stocks, 1VKTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Viking Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.